Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.6m USD

EV/OCF
Enterprise Value to OCF

-3.2
Current
-2.5
Median
4.9
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-3.2
=
Enterprise Value
257.4m USD
/
Operating Cash Flow
-81.2m USD
 
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average EV/OCF: 19.1
Negative Multiple: -3.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -229 693.2
US
Abbvie Inc
NYSE:ABBV
22.8
US
Amgen Inc
NASDAQ:AMGN
18.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -248
US
E
Epizyme Inc
F:EPE
Negative Multiple: -490.2
AU
CSL Ltd
ASX:CSL
28.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -76.8
NL
argenx SE
XBRU:ARGX
Negative Multiple: -126

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A